Head and neck cancer 2022: New standards, active surveillance and second malignancy risk
Click Here to Manage Email Alerts
Research in 2022 spotlighted several innovative and potentially effective treatment regimens for head and neck cancer.
Other studies highlighted the role of active surveillance for low-risk thyroid cancer, the impact of a nutrient-rich diet on survival, and insights into risk for second primary lung cancer among head and neck cancer survivors.
Healio shares the following developments in head and neck cancer research and treatment from the past year that may be relevant to your practice.
1. Active surveillance of newly diagnosed thyroid cancer appeared to be a viable alternative to surgery for certain patients with low-risk disease. Read more.
2. The addition of pembrolizumab (Keytruda, Merck) to chemoradiotherapy conferred an EFS benefit among patients with locally advanced head and neck squamous cell carcinoma. Read more.
3. Patients with head and neck cancer who consumed a diet high in nutrients found to deter chronic disease exhibited a 93% reduced risk for death due to any cause during the first 3 years after diagnosis. Read more.
4. Induction chemotherapy with paclitaxel, cisplatin and capecitabine improved outcomes compared with cisplatin and fluorouracil among patients with advanced nasopharyngeal carcinoma. Read more.
5. The addition of docetaxel to radiation prolonged DFS and OS for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma. Read more.
6. Intensity-modulated radiotherapy conferred disease control and survival outcomes comparable to concurrent chemoradiotherapy but with less toxicity among patients with low-risk nasopharyngeal carcinoma. Read more.
7. Capecitabine maintenance therapy significantly prolonged PFS among patients with newly diagnosed metastatic nasopharyngeal carcinoma who achieved disease control after capecitabine-containing induction chemotherapy. Read more.
8. Preoperative counseling and perioperative pain management strategies significantly reduced opioid prescriptions at discharge for patients who underwent lateral neck dissection for thyroid cancer. Read more.
9. The addition of tislelizumab (BGB-A317, BeiGene) to chemotherapy conferred a clinically meaningful PFS benefit among patients with recurrent or metastatic nasopharyngeal cancer. Read more.
10. A follow-up strategy without radioiodine appeared noninferior to an ablation strategy with radioiodine among patients with low-risk thyroid cancer undergoing thyroidectomy. Read more.
11. Mid-treatment imaging helped guide de-escalation of radiation for certain patients with oropharynx cancer. Read more.
12. Oropharyngeal cancer incidence and mortality have increased steadily among men in the United States during the past 2 decades. Read more.
13. Among adults receiving treatment for low-risk thyroid cancer, negative emotions may play an important role in decision-making. Read more.
14. A cutoff of age 15 years for pediatric differentiated thyroid cancer care may be more appropriate than the American Thyroid Association’s cutoff of 18 years due to risk factors related to survival rates. Read more.
15. Survivors of head and neck cancer appeared at increased risk for a second primary lung cancer. Read more.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts